
## Yan Peng

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/366397/publications.pdf Version: 2024-02-01



YAN DENC

#	Article	IF	CITATIONS
1	Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. Biomarkers in Medicine, 2018, 12, 813-820.	1.4	95
2	Decreased Androgen Receptor Expression Is Associated With Distant Metastases in Patients With Androgen Receptor–Expressing Triple-Negative Breast Carcinoma. American Journal of Clinical Pathology, 2012, 138, 511-516.	0.7	83
3	Acid incubation causes exocytic insertion of NHE3 in OKP cells. American Journal of Physiology - Cell Physiology, 2000, 279, C410-C419.	4.6	73
4	The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers, 2020, 12, 2081.	3.7	71
5	KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer. Neoplasia, 2014, 16, 247-256.e2.	5.3	69
6	ET <sub>B</sub> receptor activation causes exocytic insertion of NHE3 in OKP cells. American Journal of Physiology - Renal Physiology, 2001, 280, F34-F42.	2.7	51
7	Cutaneous and mammary apocrine carcinomas have different immunoprofiles. Human Pathology, 2014, 45, 320-326.	2.0	47
8	Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers. Cell, 2021, 184, 4531-4546.e26.	28.9	42
9	False-Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions. American Journal of Clinical Pathology, 2008, 130, 21-27.	0.7	36
10	CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy. BMC Cancer, 2018, 18, 813.	2.6	35
11	Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. Cancer Discovery, 2020, 10, 1706-1721.	9.4	35
12	Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metabolism, 2022, 34, 90-105.e7.	16.2	33
13	Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. Oncotarget, 2017, 8, 54364-54377.	1.8	32
14	The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer. Cancers, 2021, 13, 6209.	3.7	26
15	Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. Human Pathology, 2014, 45, 249-258.	2.0	22
16	Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. Human Pathology, 2015, 46, 1829-1835.	2.0	22
17	Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells, 2020, 9, 1135.	4.1	22
18	ZHX2 promotes HIF1Î $\pm$ oncogenic signaling in triple-negative breast cancer. ELife, 2021, 10, .	6.0	21

Yan Peng

#	Article	IF	CITATIONS
19	Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors. Human Pathology, 2014, 45, 802-809.	2.0	18
20	Lztfl1/BBS17 controls energy homeostasis by regulating the leptin signaling in the hypothalamic neurons. Journal of Molecular Cell Biology, 2018, 10, 402-410.	3.3	15
21	Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF–driven Signaling Axis. Molecular Cancer Research, 2018, 16, 1761-1772.	3.4	15
22	Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Human Pathology, 2018, 73, 176-183.	2.0	14
23	Roles of p53 and p16 in triple-negative breast cancer. Breast Cancer Management, 2013, 2, 537-544.	0.2	13
24	Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nature Cancer, 2022, 3, 866-884.	13.2	8
25	Collision Tumor of Endometrial Large Cell Neuroendocrine Carcinoma and Low-Grade Endometrial Stromal Sarcoma: A Case Report and Review of the Literature. International Journal of Surgical Pathology, 2020, 28, 569-573.	0.8	5
26	HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Current Oncology, 2021, 28, 1608-1617.	2.2	3
27	Cutaneous Colocalized Invasive Poorly Differentiated Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma of the Head and Neck Region. JAMA Otolaryngology, 2009, 135, 606.	1.2	2
28	Distinct Immunophenotypic Features of Ovarian Microcystic Stromal Tumor. American Journal of Clinical Pathology, 2014, 142, A239-A239.	0.7	0
29	Abstract P1-02-14: A comparative analysis of clinical and pathologic characteristics of patients with HER2 positive breast cancer treated with neoadjuvant versus adjuvant anti-HER2 therapy: Analysis of 397 cases. Cancer Research, 2022, 82, P1-02-14-P1-02-14.	0.9	0